Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.44 |
| ▸ | FTO | Q9C0B1 | 4/20 | 0.42 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 3/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.37 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.36 |
| ▸ | KDM6B | O15054 | 1/20 | 0.36 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30415076 | 0.78 | PTPN11 (0.46) | KDM4EMAPT | |
| SCHEMBL288626 | 0.77 | KDM4E (0.44) | EGLN1FTOEGLN2KDM5BKDM2A | |
| SCHEMBL2295486 | 0.73 | MKNK1 (0.39) | KDM5BKDM2AKDM4EKDM4CKDM6B | |
| Hydrochloric Acid SCHEMBL19211726 | 0.71 | MKNK1 (0.38) | KDM5BKDM2AKDM4EKDM4CKDM6B | |
| SCHEMBL22554098 | 0.68 | DAO (0.45) | EGLN1FTOEGLN2 | |
| SCHEMBL821327 | 0.67 | FTO (0.41) | EGLN1FTOEGLN2KDM5BKDM2A | |
| SCHEMBL8581111 | 0.65 | KDM4E (0.61) | KDM4EMAPTHIF1ASLC22A6SLC22A8 | |
| SCHEMBL29195034 | 0.65 | PREP (0.52) | EGLN1FTOEGLN2KDM5BKDM4E | |
| SCHEMBL3683242 | 0.63 | FTO (0.59) | EGLN1FTOEGLN2KDM5BKDM2A | |
| SCHEMBL3242636 | 0.63 | KDM4E (0.55) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039885-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENITOR CELLS | FIBROGEN, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110039879-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | FibroGen ,Inc. (US) | 2011-02-17 | — | — | US | disclosed |
| EP-2231156-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | Fibrogen, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2231157-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENTIOR CELLS | Fibrogen, Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2227232-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | Fibrogen, Inc. (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20100144737-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | FIBROGEN, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2009075826-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009075824-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENTIOR CELLS | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009075822-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | FIBROGEN, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144737-A1 | METHODS FOR INHIBITING T HELPER CELL DIFFERENTIATION | NFATC1, CD4, IL2 | EGLN1 238/4885FTO 4088/4885EGLN2 215/4885 |
| US-20110039879-A1 | METHODS FOR INCREASING WHITE BLOOD CELLS | THPO, MCL1, CD14 | EGLN1 1148/4885FTO 4102/4885EGLN2 866/4885 |
| US-20110039885-A1 | METHODS FOR INCREASING ENDOTHELIAL PROGENITOR CELLS | CXCL12, SDF4, LIPG | EGLN1 501/4885FTO 3763/4885EGLN2 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.